You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 10, October 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders
 •Neoplasms
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Glimpse of Future Management of Melanoma

Alistair J. Cochran, MD

Arch Dermatol. 2009;145(10):1176-1177.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The modern techniques of lymphatic mapping and sentinel node (SN) biopsy (LM/SNB) were introduced for the management of cutaneous melanoma in 19921 and quickly found wide acceptance. They have also been applied to the management of squamous carcinoma of various sites, Merkel cell carcinoma, breast cancer, cancer of the upper and lower gastrointestinal tract, and gynecological malignant neoplasms.2 The presence or absence of metastatic melanoma in the SN provides optimal staging and is the most accurate available indicator of prognosis.3 There is less unanimity in regard to the therapeutic role of LM/SNB. Many clinicians (including me) believe that LM/SNB, with immediate completion lymph node dissection if the SN contains tumor, is a more effective way to treat patients with melanoma and early metastases to the lymph nodes than observation with delay of lymph node dissection until the tumor-containing nodes become clinically detectable. During such observation, the . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Highly Sensitive Multivariable Assay Detection of Melanocytic Differentiation Antigens and Angiogenesis Biomarkers in Sentinel Lymph Nodes With Melanoma Micrometastases
Dominique Vitoux, Samia Mourah, Delphine Kerob, Olivier Verola, Nicole Basset-Seguin, Michel Baccard, Noel Schartz, Laurence Ollivaud, Alain Archimbaud, Jean-Marie Servant, Marc Revol, Marie-Elisabeth Toubert, Marie-Pierre Podgorniak, François Plassa, Raphael Porcher, and Céleste Lebbé
Arch Dermatol. 2009;145(10):1105-1113.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.